These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27609503)

  • 1. Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension.
    Dudenbostel T; Calhoun DA
    Am J Hypertens; 2017 Feb; 30(2):103-109. PubMed ID: 27609503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of aldosterone antagonists in the management of resistant hypertension.
    Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Oct; 7(5):343-7. PubMed ID: 16157075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of aldosterone blockade in resistant hypertension.
    Egan BM; Li J
    Semin Nephrol; 2014 May; 34(3):273-84. PubMed ID: 25016399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary aldosteronism: diagnostic and therapeutic considerations.
    Nishizaka MK; Calhoun DA
    Curr Cardiol Rep; 2005 Nov; 7(6):412-7. PubMed ID: 16256009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperaldosteronism as a common cause of resistant hypertension.
    Calhoun DA
    Annu Rev Med; 2013; 64():233-47. PubMed ID: 23092384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary aldosteronism: a new insight into pathogenesis, diagnosis, and treatment in hypertensive patients.
    Hyla-Klekot L; Kokot F
    Pol Arch Med Wewn; 2013; 123(10):547-51. PubMed ID: 24104388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
    Colussi G; Catena C; Sechi LA
    J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.
    Gaddam KK; Pratt-Ubunama MN; Calhoun DA
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):353-9. PubMed ID: 16716096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
    Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Aldosteronism: Present and Future.
    Funder JW
    Vitam Horm; 2019; 109():285-302. PubMed ID: 30678860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reviving the use of aldosterone inhibitors in treating hypertension in obesity.
    Huby AC; Belin De Chantemèle EJ
    Am J Physiol Regul Integr Comp Physiol; 2015 Nov; 309(9):R1065-7. PubMed ID: 26157057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy-resistant hypertension--the value of aldosterone antagonists].
    Quack I; Reincke M; Rump LC
    MMW Fortschr Med; 2007 Nov; 149(46):39-40. PubMed ID: 18069192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
    Whaley-Connell A; Johnson MS; Sowers JR
    Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
    Morimoto S; Ichihara A
    Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.